Comparative Effectiveness of COPD Treatments

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3954 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-01

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the effectiveness of maintenance treatment of Chronic obstructive pulmonary disease (COPD) with the combination of a long-acting bronchodilators (LABA and the long-acting muscarinic antagonists (LAMA) tiotropium (LABA-TIO)) compared with the combination of a LABA and an ICS (LABA-ICS) on the time to COPD exacerbation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Triple Therapy in COPD

NCT03724877

Pulmonary Disease, Chronic Obstructive

COMPLETED

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

NCT04138758

COPD

COMPLETED

Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD

NCT05927155

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)

NCT02173691

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA

NCT02546349

COPD

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects diagnosed with COPD

Chronic obstructive pulmonary disease

LABA and the LAMA tiotropium (LABA-TIO)

Intervention Type DRUG

combinational drug

LABA and an ICS (LABA-ICS)

Intervention Type DRUG

combinational drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LABA and the LAMA tiotropium (LABA-TIO)

combinational drug

Intervention Type DRUG

LABA and an ICS (LABA-ICS)

combinational drug

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FORVENT, SPIRIVA, SRIVASSO

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* New users of long-acting bronchodilators, LABA and tiotropium on the same date or of LABA and ICS, either as a fixed-dose combination or free combination, on the same date between January 2002 and December 2015
* Diagnosis of COPD and age ≥ 55 years